Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.
Kabir Mody, MD
Advertisement
Articles by Kabir Mody, MD
Kabir Mody, MD, discusses the unique approach used to deliver Y-90 glass microspheres to patients with unresectable hepatocellular carcinoma.
Kabir Mody, assistant professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, highlights the recent treatment advances for patients with hepatocellular carcinoma.
Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses treatment options for patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Dr. Mody on Progress Made With Y-90 in Hepatocellular CarcinomaFebruary 18th 2021
Dr. Mody Discusses Treatment Options for HCCNovember 12th 2018
Dr. Mody Highlights Treatment Advances in HCCFebruary 7th 2019
Dr. Mody on the Unique Delivery Approach for Y-90 in HCCJanuary 27th 2021
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5